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Considering the potential of ﬂavonoids in reversing the P-glycoprotein (P-gp)emediated multidrug
resistance, this work aimed to assess the combined effects of silymarin and (-)-epigallocatechin gallate
(EPG) on the pharmacokinetics of the P-gp substrates oxcarbazepine (OXC) and licarbazepine (LIC). Rats
were pre-treated intraperitoneally with silymarin (25 mg/kg), EPG (25 mg/kg), silymarin/EPG (12.5/
12.5 mg/kg; 6.25/18.75 mg/kg; 18.75/6.25 mg/kg) or verapamil (25 mg/kg, reference P-gp inhibitor)
before the intraperitoneal administration of OXC (50 mg/kg). Pre-treatment with dual silymarin/EPG
combinations originated peak plasma concentrations of OXC and LIC (pharmacologically active metab-
olite of OXC) similar to those achieved in the presence of verapamil (positive control). Moreover, the
effects promoted by silymarin/EPG combinations on the magnitude of systemic drug exposure to OXC
and LIC were also reﬂected in the corresponding drug levels attained in the brain (biophase). These
ﬁndings evidence the synergistic effect of silymarin and EPG in enhancing the degree of systemic
exposure to OXC and LIC in rats, which occurred in a comparable extent to that observed with verapamil.
Hence, our ﬁndings support the combination of ﬂavonoid-type P-gp inhibitors and P-gp substrate
antiepileptic drugs as a potential therapeutic strategy for the management of pharmacoresistant
epilepsy.
© 2017 Elsevier Ltd. All rights reserved.ea under the concentration-
sampling time; AUC0-∞, AUC
ncentration; Cmax, peak con-
ome P450; DAD, diode array
formance liquid chromatog-
constant; LIC, licarbazepine;
dence time; OXC, oxcarbaze-
tandard error of the mean; t1/
to reach Cmax.
, CICS-UBI e Health Sciences
ante D. Henrique, 6200-506
.1. Introduction
In the recent years, several indigenous medicinal plants have
been identiﬁed as possessing endogenous bioactive compounds
that can be used to treat different human ailments (Ekor, 2014;
Newman and Cragg, 2016). Actually, medicinal herbs are being
increasingly used by the general population in the Western world
and are also a subject of study interest by the scientiﬁc community
(Lee, 2000; Pathak and Udupa, 2010). Particularly, the therapeutic
potential of ﬂavonoid compounds has been gaining relevance over
the last years. These phytochemical constituents are a group of
structurally related compounds present in the human diet,
being widespread in vegetables, fruits, ﬂowers, seeds and
grains (Bansal et al., 2009; Mohana et al., 2016). The chemical
diversity of ﬂavonoid structures is responsible for a wide range of
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proliferative, pro-apoptotic, free-radical scavenging, antioxidant,
antitumor, antimicrobial, antiviral, hormonal and anticonvulsant
properties (Buer et al., 2010; Ferreira et al., 2015; Hoensch and
Oertel, 2015).
Accordingly, the exploitation of potentially beneﬁcial in-
teractions between ﬂavonoid-type compounds with multiple bio-
activities and clinically available drugs could be a valuable strategy
in certain circumstances, namely in overcoming some mechanisms
underlying multidrug resistance (Boumendjel et al., 2002; Pathak
and Udupa, 2010; Peng et al., 2006; Thomas and Coley, 2003).
Actually, in spite of the current availability of numerous antiepi-
leptic drugs (AEDs) in the clinical practice, the drug-resistant epi-
lepsy is an unmet medical need, affecting about one-third of
epilepsy patients (Baulac et al., 2015; Franco et al., 2016; Sharma
et al., 2015; Ventola, 2014). The multidrug transporter hypothesis
remains as one of the main accepted theories to explain the phar-
macoresistance to AEDs (L€oscher et al., 2013). This hypothesis
emphasizes the role of the overexpression and/or overactivity of
multidrug efﬂux transporters, such as the P-glycoprotein (P-gp), in
capillary endothelial cells of the blood-brain barrier, restricting the
AEDs uptake into the brain of non-responsive patients (L€oscher
et al., 2013; L€oscher and Potschka, 2005; L€oscher and Sills, 2007;
Zhang et al., 2012). Moreover, P-gp is also largely expressed in the
luminal membrane of small intestinal epithelial cells and in the
apical membranes of excretory cells, such as hepatocytes and kid-
ney proximal tubule epithelial cells, determining the pharmacoki-
netics and drug biodisposition of P-gp substrate drugs
(Prachayasittikul and Prachayasittikul, 2016; Wessler et al., 2013).
Regarding this matter, the P-gp inhibition arises as an attractive
therapeutic approach to reverse the drug-resistant phenotype in
epilepsy, particularly because several AEDs including oxcarbaze-
pine (OXC) and its pharmacologically active metabolite licarbaze-
pine (LIC) have been identiﬁed as substrates of this drug efﬂux
pump (Fig. 1) (Zhang et al., 2012).
The recognition of the implication of the P-gp-mediated
multidrug resistance not only in epilepsy but also in many other
clinically important diseases has led to concerted efforts to search
for therapeutically useful P-gp inhibitors (Feldmann and Koepp,
2016; French et al., 2013; Ste˛pien et al., 2012). In this context,
over the last years, aiming at developingmore selective and safer P-
gp inhibitors than those of the early generations, a great attention
has been given to naturally occurring ﬂavonoids as selective and
non-cytotoxic P-gp inhibitors (Bansal et al., 2009; Ferreira et al.,
2015; Mohana et al., 2016). Indeed, there are several in vitro and
in vivo studies describing the potential of ﬂavonoid compounds as
P-gp inhibitors, including silymarin and (-)-epigallocatechin gallate
(EPG) (Fig. 1) (Chung et al., 2005; Jodoin et al., 2002; Kitagawa,
2006; Park et al., 2012; Zhang and Morris, 2003a).
Taking into account the daily consumption of complex mixtures
of ﬂavonoid compounds, exhibiting a panoply of biological activ-
ities, it is of great interest the evaluation of the synergistic phar-
macological effect of these compounds. Thus, the study of the
synergistic activities of dual ﬂavonoid combinations as P-gp in-
hibitors emerges as a valuable approach, which may be useful to
circumvent the multidrug resistance mediated by P-gp. In fact, the
combination of different ﬂavonoids as P-gp inhibitors is supported
by the recognition that there are multiple binding sites for sub-
strates and inhibitors on P-gp (Yang and Liu, 2004). Hence, in the
path to develop a strategy to reverse the P-gp-mediated AED
resistance, the inﬂuence of the combined use of silymarin and EPG
on the pharmacokinetics of OXC, a well-known P-gp substrate
widely used in the treatment of epilepsy seizures, was evaluated
herein.2. Materials and methods
2.1. Drugs and materials
Standards of silymarin, verapamil (a reference P-gp inhibitor
used as positive control) and primidone (used as internal standard)
were purchased from Sigma-Aldrich (St. Louis, MO, USA), while EPG
was obtained from TCI (Tokyo, Japan). Carboxymethylcellulose so-
dium salt and dimethyl sulfoxide (DMSO) were obtained from
Sigma-Aldrich (St. Louis, MO, USA). Oral suspension of OXC (Tri-
leptal® 60 mg/mL), sodium chloride 0.9% solution for injection
(Labesfal, Portugal), heparin sodium 5000 U.I./mL for injection (B.
Braun Medical, Portugal), and pentobarbital (Eutasil® 200 mg/mL,
Ceva Saúde Animal; used as anaesthetic drug) were commercially
acquired. Introcan® Certo IV indwelling cannula (22G;
0.9  2.5 mm) made of polyurethane were supplied from B. Braun
Melsungen AG (Melsungen, Germany).
Methanol and acetonitrile, both of high-performance liquid
chromatography (HPLC) gradient grade, and ethyl acetate were
purchased from Fisher Scientiﬁc (Leicestershire, United Kingdom).
The ultra-pure water (HPLC grade, >18 MU cm) was prepared by
means of a Milli-Q water apparatus from Millipore (Milford, MA,
USA).
2.2. Animals
Healthy adult male Wistar rats (381 ± 16 g) of approximately 15
weeks old were obtained from local animal facilities (Faculty of
Health Sciences of the University of Beira Interior, Covilh~a,
Portugal). The rats were maintained under controlled environ-
mental conditions, in particular, the temperature (20 ± 2 C),
relative humidity (55 ± 5%) and light/dark cycle (12 h). During all
the experimental procedures, tap water and the standard rodent
diet (4RF21, Mucedola, Italy) were available ad libitum. All experi-
mental and care procedures were conducted in accordance with
the European Directive (2010/63/EU) regarding the protection of
laboratory animals used for scientiﬁc purposes. In addition, the
experimental procedures were reviewed and approved by the
Portuguese National Authority for Animal Health, Phytosanitation
and Food Safety (DGAV e Direç~ao Geral de Alimentaç~ao e
Veterinaria).
2.3. Systemic pharmacokinetic study
At the night on the day before the pharmacokinetic studies, a
lateral tail vein of each rat was cannulated under anaesthesia
[pentobarbital 60 mg/kg; intraperitoneal (i.p.) injection] by inser-
tion of an Introcan® Certo IV indwelling cannula (22G;
0.9 2.5mm) that was used for serial blood sampling. The rats fully
recovered from anaesthesia overnight, and then in the morning
were subjected to pharmacological treatments, all administered by
i.p. route as mentioned below. The conscious and freely moving rats
were appropriately restrained only at the moment of administra-
tion of the treatments and blood collections.
In this pharmacokinetic study, a total of thirty-six rats were
used. The ﬂavonoids silymarin and EPG were tested individually
and in dual combinations at three ﬁxed-ratios (1:1; 1:3 and 3:1)
taking into account the ﬁnal dose of 25 mg/kg. The animals were
randomly assigned to one of six groups [experimental and control
(verapamil) groups, n ¼ 6] receiving the i.p. pre-treatment with
silymarin (25 mg/kg), EPG (25 mg/kg), silymarin/EPG 1:1 (12.5/
12.5 mg/kg; ﬁxed-ratio combination of 1:1), silymarin/EPG 1:3
(6.25/18.75 mg/kg; ﬁxed-ratio combination of 1:3), silymarin/EPG
3:1 (18.75/6.25mg/kg; ﬁxed-ratio combination of 3:1) or verapamil
(25 mg/kg, positive control group). The compounds (EPG, silymarin
Fig. 1. Chemical structures of oxcarbazepine and its active metabolite licarbazepine, the ﬂavonoid (-)-epigallocatechin gallate and some constituents of silymarin (silybinin,
silychristin and silydianin).
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carboxymethylcellulose sodium salt aqueous solution 0.5% (m/v),
containing the ﬁnal suspension a concentration of 5% DMSO (v/v).
Appropriate volumes of these suspensions (5 mL/kg of rat weight)
were administered by i.p. route to the respective groups. After 1-h
period, all the groups of rats were treated with OXC (50 mg/kg, i.p.).
The OXC dose was chosen taking into account the work of Hainzl
et al. (2001), in which a OXC dose of 20 mg/kg was used. Howev-
er, knowing that reduced LIC concentrations were found in rat
plasma and brain (Hainzl et al., 2001), in the current work we
considered a dose of OXC 2.5-fold higher (50 mg/kg) in order to
characterize the LIC pharmacokinetic proﬁle as much as possible.
The commercial suspension of OXC (Trileptal® 60 mg/mL) was
appropriately diluted with carboxymethylcellulose sodium salt
aqueous solution 0.5% (m/v) and an appropriate volume was
administered considering a total volume of administration of
10 mL/kg of rat weight. Multiple serial blood samples of approxi-
mately 0.3 mL were collected through the cannula inserted in a
lateral tail vein into heparinized tubes before and at 0.5, 1, 1.5, 2, 3,
4, 6, 8 and 12 h after OXC administration. The blood samples were
centrifuged at 4000 rpm for 10 min (4 C) to separate the plasma
that was collected and stored at 20 C until analysis.2.4. Plasma-to-brain biodistribution study
To further investigate the potential effects of dual silymarin/EPG
combinations on the plasma-to-brain distribution of OXC, aseparate study was performed. In this study, twelve rats were
randomly assigned to one of four groups (n¼ 3), which received the
pre-treatment with silymarin/EPG 1:1, silymarin/EPG 1:3, sily-
marin/EPG 3:1 or verapamil (25 mg/kg; positive control group).
One hour after pre-treatment administration, a single dose of OXC
(50 mg/kg) was given by i.p. route to rats of all groups. The ﬂavo-
noids and OXC suspensions were prepared as previouslymentioned
in Section 2.3. Then, at 1.5 h post OXC dosing the rats were sacri-
ﬁced by decapitation and the tissues of interest were obtained
(blood and brain). Blood (approximately 0.3 mL) was immediately
collected into heparinized tubes, and then the brain was quickly
removed and weighed. The blood samples were centrifuged at
4000 rpm for 10 min (4 C) to separate the plasma. The brain tissue
was homogenized in 0.1 M sodium phosphate buffer at pH 5.0
(4 mL per gram of tissue) using an Ultra-Turrax® tissue homoge-
nizer and centrifuged at 13 500 rpm for 10 min (4 C). The plasma
and brain homogenate supernatant samples were collected and
stored at 20 C until analysis.2.5. Bioanalytical method validation
Plasma and brain concentrations of OXC and its active metabo-
lite (LIC) were determined using a liquid-liquid extraction pro-
cedure followed by HPLC analysis coupled to a diode array detector
(DAD), which is based on a previously published assay with minor
modiﬁcations (Ferreira et al., 2016). This technique was posteriorly
validated in rat plasma and brain matrices in agreement with the
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(European Medicines Agency, 2011; U.S. Food and Drug
Administration, 2013) for speciﬁc validation parameters such as
linearity, lower limit of quantiﬁcation (LLOQ), accuracy, precision
and recovery.
The linearity was assessed using three calibration curves pre-
pared with six spiked rat plasma or brain calibration standards,
assayed on three different days (n ¼ 3). The calibration standards
set at the concentration ranges of 0.1e25 mg/mL for OXC and
0.05e40 mg/mL for LIC were daily prepared by spiking aliquots of
blank plasma or brain homogenate with each one of these com-
bined solutions. The stock solution of the IS was also prepared in
methanol (2 mg/mL) and the working solution (500 mg/mL) was
obtained after diluting an appropriate volume of the stock solution
with water-methanol (50:50, v/v). A plot of the ratio between the
analyte and internal standard peak areas, as function of the corre-
sponding nominal concentrations, were used to construct the
calibration curves. The data were ﬁtted to a weighted linear
regression analysis employing the weighting factor that yielded the
best ﬁt of peak-area ratios versus concentration (Almeida et al.,
2002). The lowest concentration of the target analytes in plasma
or brain samples that can be quantiﬁed reliably, with an acceptable
accuracy and precision, was used to establish the lowest calibration
standard of the calibration curves and corresponded to the LLOQ.
The interday precision and accuracy of the assay were evaluated on
three consecutive days (n ¼ 3), using four quality control (QC)
samples representing the LLOQ (QCLLOQ), low (QC1), medium (QC2)
and high (QC3) ranges of the calibration curves. These concentra-
tions were 0.1, 0.3, 12.5 and 22.5 mg/mL for OXC; and 0.05, 0.15, 20
and 36 mg/mL for LIC. Similarly, ﬁve sets of QC samples analysed in a
single day (n ¼ 5) were used to assess the intraday precision and
accuracy. The acceptance criteria were those referred in the bio-
analytical method validation guidelines, this is, the intra and
interday precision [expressed as percentage of coefﬁcient of vari-
ation (CV)] must be lower than or equal to 15% (or 20% in the LLOQ)
and the accuracy (expressed as percentage of bias) must be within
± 15% (or ± 20% in the LLOQ). Lastly, three QC samples (QC1, QC2 and
QC3) were used to determine the absolute recovery of the analytes
from the samples. This parameter was calculated through the
comparison between the analytes peak areas from extracted rat
plasma or brain QC samples with those obtained after direct in-
jection of non-extracted solutions at the same nominal concen-
trations (n ¼ 5).
2.6. Drug analysis
Each aliquot (100 mL) of rat plasma or brain homogenate su-
pernatant, spiked with 20 mL of the internal standard working so-
lution (primidone, 500 mg/mL), was added of 300 mL of ice-cold
acetonitrile and 1 mL of ethyl acetate (liquid-liquid extraction sol-
vent). Then, the mixture was vortex-mixed for 30 s and centrifuged
at 13 500 rpm for 3 min. The upper organic layer was transferred to
a clean glass tube and, afterwards, the sample was re-extracted
twice more with ethyl acetate (1 mL each time) using the condi-
tions previously described. The whole organic extract was evapo-
rated to dryness under a nitrogen stream at 45 C and then
reconstituted with 100 mL of the mobile phase. Finally, an aliquot
(20 mL) of this ﬁnal sample was injected into the chromatographic
system. The LLOQwas established at 0.1 mg/mL for OXC and 0.05 mg/
mL for LIC in both matrices (plasma and in brain tissue
homogenate).
The chromatographic analysis was carried out using an HPLC-
DAD system (Shimadzu LC-2010A HT Liquid Chromatography and
Shimadzu SPD-M20A). All instrumental parts were automatically
controlled by LabSolutions software (Shimadzu, Kyoto, Japan). Thechromatographic separation of OXC, LIC and primidone (internal
standard) was carried out at 35 C on a reversed-phase LiChro-
CART® Purospher Star column (C18, 55 mm  4 mm, 3 mm particle
size; Merck KGaA, Darmstadt, Germany) by isocratic elution with a
mobile phase composed of water/methanol/acetonitrile (69:25:6,
v/v/v) pumped at a ﬂow rate of 1.0 mL/min. The wavelength of
215 nm was selected for the detection of LIC, and 230 nm for OXC
and primidone (internal standard).
2.7. Pharmacokinetic analysis
The peak concentration (Cmax) and the time to reach Cmax (tmax)
of OXC and LIC in plasma were obtained directly from the experi-
mental data. The remaining pharmacokinetic parameters were
estimated from the individual plasma concentration-time proﬁles
determined at each time point by non-compartmental pharmaco-
kinetic analysis using the WinNonlin® version 5.2 (Pharsight Co,
Mountain View, CA, USA). For each rat, the estimated pharmaco-
kinetic parameters included the area under the concentration-time
curve (AUC) from time zero to the last sampling time (AUC0-t) that
was calculated by the linear trapezoidal rule; the AUC from time
zero to inﬁnite (AUC0-∞), determined from AUC0-t þ (Clast/kel),
where Clast is the last quantiﬁable concentration and kel the
apparent terminal rate constant calculated by log-linear regression
of the terminal segment of the concentration-time proﬁle. Addi-
tionally, the apparent terminal elimination half-life (t1/2el) and
mean residence time (MRT) were also estimated. The concentra-
tions lower than the limit of quantiﬁcation of the assay were taken
as zero for all calculations.
2.8. Statistical analysis
Data were reported as the mean ± standard error of the mean
(SEM), unless otherwise noted. Comparisons between the positive
control (verapamil) group vs experimental groups were performed
using one-way ANOVA with the post hoc Dunnett's test, except for
the tmax parameter where the nonparametric Kruskal-Wallis with
the post hoc Dunn's test was applied. The differences were
considered statistically signiﬁcant for p-values lower than 0.05
(p < 0.05).
3. Results
3.1. Bioanalytical method validation
Through the results obtained in the validation assays, it can be
concluded that the HPLC-DAD methodology was reliable in sup-
porting the pharmacokinetics and biodistribution studies herein
performed. Actually, the calibration curves obtained in rat plasma
and brain demonstrated a consistent correlation between analyte-
IS peak area ratios and the corresponding nominal concentrations,
being linear (r2  0.9920) for OXC and LIC within the deﬁned
concentration ranges. Those calibration curves were subjected to
weighted linear regression analysis using 1/x2 as the weighting
factor, considering the wide concentration ranges, and in order to
compensate the heteroscedasticity detected. Additionally, the LLOQ
values, as well the data for inter and intraday precision and accu-
racy fulﬁlled the acceptance criteria established by the interna-
tional guidelines (European Medicines Agency, 2011; U.S. Food and
Drug Administration, 2013). Indeed, the overall intra and interday
imprecision (%CV) in rat plasma and brain was lower than 11.57%
for OXC and lower than 11.56% for LIC; whereas the overall intra and
interday inaccuracy (%bias) in rat plasma and brain ranged
between 0.53 and 11.15% for OXC and between 12.35 and 7.26%
for LIC. The absolute recovery values demonstrated a good recovery
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values equal to or higher than 80.0%. Actually, the absolute re-
coveries for OXC ranged between 80.0e85.8% in rat plasma and
82.1e89.5% in rat brain, and for LIC ranged between 91.1e99.6% and
87.4e91.6%, respectively.
3.2. Effects of silymarin, EPG and their combinations on the
systemic pharmacokinetics of OXC
Themean plasma concentration-time proﬁles (n¼ 6) of OXC and
its active metabolite LIC obtained in rats after pre-treatment with a
single i.p. dose of silymarin (25 mg/kg), EPG (25 mg/kg), silymarin/
EPG 1:1 (12.5/12.5 mg/kg), silymarin/EPG 1:3 (6.25/18.75 mg/kg),
silymarin/EPG 3:1 (18.75/6.25 mg/kg) or verapamil (25 mg/kg,
positive control), followed by an i.p. administration of OXC (50 mg/
kg), are shown in Fig. 2.
As represented in Fig. 2A, plasma OXC concentrations deter-
mined in the rats pre-treated with ﬂavonoid compounds were
more comparable to those achieved in the positive control
(verapamil) group during the ﬁrst 2 h after OXC administration.
However, this similarity in the OXC pharmacokinetic proﬁles was
more marked for the three ﬂavonoid combinations groups (p-
values were usually higher than 0.05 in relation to verapamil
group). Although none of the individual ﬂavonoids (silymarin and
EPG) or dual ﬂavonoid combinations enable to achieve higher
plasma OXC concentrations than those reached by the adminis-
tration of the classic P-gp inhibitor (verapamil), these results are
still interesting as these dual ﬂavonoid combinations (silymarin/
EPG) are potentially safer than verapamil. As in this study our
primary objective was to demonstrate the non-inferiority of
ﬂavonoid combinations in relation to verapamil, a negative control
(vehicle) group was not included in the experimental design.
However, in previous experiments, a vehicle group (a group of rats
pre-treated with the corresponding volume of the compound's
vehicle instead of ﬂavonoids or verapamil formulations) was
considered, and such data were also included in Fig. 2 only for
supportive purposes (dashed line). Indeed, visually we can observe
that the individual ﬂavonoids silymarin and EPG expressively
increased the plasma concentration levels of OXC around the tmax
period (1.5 h) in comparison with the drug levels found in the rats
of the vehicle group. Nevertheless, the pre-treatment with sily-
marin/EPG combinations, in the three tested ﬁxed-ratios, permittedFig. 2. Mean plasma concentration-time proﬁles of oxcarbazepine (A) and its active metab
(25 mg/kg; S), EPG (25 mg/kg; E), silymarin/EPG 1:1 (12.5/12.5 mg/kg; ﬁxed-ratio combi
silymarin/EPG 3:1 (18.75/6.25 mg/kg; ﬁxed-ratio combination of 3:1), or verapamil (25 m
dashed line represents the data of a vehicle control group from previous experiments (ra
ﬂavonoids or verapamil formulations). Data are expressed as the mean values ± standard erro
(positive control) group vs experimental groups were performed using one-way ANOVA wi
statistically signiﬁcant differences in relation to the verapamil group (p < 0.05).to achieve even greater concentrations of OXC at this post-dose
time period. In fact, as previously mentioned, these concentra-
tions were closer to those obtained in the verapamil (positive
control) group. Analysing the mean pharmacokinetic proﬁles ob-
tained for LIC (Fig. 2B), and comparing these proﬁles with those
obtained for the parent drug (OXC), it is evident a close similarity in
the pattern of the concentrationetime curves. However, the
magnitude of the mean LIC concentrations in plasma were 15- to
18-fold lower than those of OXC.
The main plasma pharmacokinetic parameters obtained for OXC
and LIC after non-compartmental analysis of their mean
concentration-time proﬁles are presented in Table 1. As expected,
the quantitative values found for the pharmacokinetic parameters
conﬁrm the observational analysis previously performed to the
mean plasma pharmacokinetic proﬁles. The pre-treatment with the
individual ﬂavonoids, or their dual combinations, did not signiﬁ-
cantly change the median time (1.500e1.750 h) to reach the peak
plasma concentrations (Cmax) of OXC and LIC, when comparing to
the verapamil group. Relatively to the degree of systemic exposure
(as assessed by Cmax), statistically signiﬁcant differences were
detected for OXC, when comparing the silymarin or EPG individual
groups with the verapamil group (p < 0.05). Nevertheless, statis-
tically signiﬁcant differences were not found for the comparison
between the three experimental groups in which the ﬂavonoid
combinations were tested and the verapamil group. Actually,
whereas silymarin and EPG individually originated OXC Cmax values
inferior to verapamil in approximately 31e36%, the ﬂavonoid
combinations allowed to obtain Cmax values that only differed from
the positive control group in about 14e18%. Indeed, the positive
impact that pre-treatment with ﬂavonoids, particularly with
ﬂavonoid combinations, had on increasing the plasma concentra-
tions of OXC and LIC during the ﬁrst 2-h period after OXC admin-
istration was translated in the absence of statistically signiﬁcant
differences in the rate of systemic drug exposure when compared
to verapamil (as assessed by tmax and Cmax). However, the effect
induced by ﬂavonoids on the biodisposition of OXC and LIC seems
to be lost earlier than the effect promoted by verapamil, which was
reﬂected in the statistically signiﬁcant differences (p < 0.05) usually
found between experimental and positive control groups for the
pharmacokinetic parameters predictive of the extent of systemic
drug exposure (AUC0-t).olite licarbazepine (B) obtained, over a 12-h period, in rats pre-treated with silymarin
nation of 1:1), silymarin/EPG 1:3 (6.25/18.75 mg/kg; ﬁxed-ratio combination of 1:3),
g/kg) 1 h before the intraperitoneal administration of oxcarbazepine (50 mg/kg). The
ts pre-treated with the corresponding volume of the compound's vehicle instead of
r of the mean (SEM) of six determinations (n ¼ 6). Comparisons between the verapamil
th the post hoc Dunnett's test. Above each time point is mentioned which groups have
Table 1
Pharmacokinetic parameters estimated by non-compartmental analysis of the plasma concentration-time proﬁles of oxcarbazepine (OXC) and its active metabolite licarba-
zepine (LIC) obtained in rats after intraperitoneal pre-treatment with silymarin (25 mg/kg), (-)-epigallocatechin gallate (EPG; 25 mg/kg), silymarin/EPG (12.5/12.5 mg/kg,
ﬁxed-ratio combination of 1:1) silymarin/EPG (6.25/18.75 mg/kg, ﬁxed-ratio combination of 1:3), silymarin/EPG (18.75/6.25 mg/kg, ﬁxed-ratio combination of 3:1) or
verapamil (25 mg/kg) 1 h before a single intraperitoneal administration of OXC (50 mg/kg) (n ¼ 6, unless otherwise noted). Data are expressed as the mean values ± standard
error of the mean (SEM), exception for tmax that is expressed as the median value (range).
Parameter
tmax
(h)
Cmax
(mg/mL)
AUC0-t
(mg.h/mL)
AUCextrap
(%)
AUC0-∞
(mg.h/mL)
kel
(h-1)
t1/2el
(h)
MRT
(h)
OXC Verapamil 1.500 (1.000e2.000) 13.069 ± 0.829 64.303 ± 4.347 30.934 ± 2.280 ND ND ND ND
Silymarin 1.500 (1.000e2.000) 8.954 ± 0.622 * 41.407 ± 1.836 * 28.428 ± 2.138 ND ND ND ND
EPG 1.500 (0.500e1.500) 8.349 ± 0.771 * 34.902 ± 2.266 * 15.643a 46.419a 0.135a 5.13a 6.47a
Silymarin/EPG 1:1 1.500 (1.500e2.000) 11.243 ± 0.375 42.533 ± 2.086 * 17.858 ± 1.014b 51.514 ± 1.588b 0.190 ± 0.007b 3.67 ± 0.13b 6.35 ± 0.21b
Silymarin/EPG 1:3 1.500 (1.000e2.000) 10.711 ± 0.714 38.255 ± 1.471 * 15.425 ± 1.102c 48.450 ± 0.199c 0.174 ± 0.021c 4.27 ± 0.58c 6.14 ± 0.32c
Silymarin/EPG 3:1 1.500 (1.000e2.000) 11.014 ± 0.684 37.672 ± 2.628 * 10.934 ± 0.913b 41.287 ± 1.325b 0.179 ± 0.013b 4.03 ± 0.32b 5.33 ± 0.17b
LIC Verapamil 1.750 (1.500e4.000) 0.682 ± 0.082 4.369 ± 0.507 31.093 ± 4.807 ND ND ND ND
Silymarin 1.500 (1.500e2.000) 0.579 ± 0.056 2.855 ± 0.172 * 29.325 ± 2.293 ND ND ND ND
EPG 1.500 (1.500e1.500) 0.472 ± 0.064 1.937 ± 0.149 * 34.615 ± 3.166 ND ND ND ND
Silymarin/EPG 1:1 1.500 (1.000e2.000) 0.828 ± 0.070 2.849 ± 0.243 * 15.732 ± 0.283c 3.256 ± 0.388c 0.194 ± 0.006c 3.59 ± 0.12c 6.07 ± 0.12c
Silymarin/EPG 1:3 1.500 (1.500e2.000) 0.608 ± 0.043 2.338 ± 0.113 * 11.748 a 2.549a 0.204a 3.40a 5.51a
Silymarin/EPG 3:1 1.500 (1.000e2.000) 0.667 ± 0.080 2.166 ± 0.271 * 11.849 ± 0.915d 2.334 ± 0.167d 0.316 ± 0.087d 2.85 ± 0.79d 4.47 ± 0.85d
AUC, area under the concentration-time curve; AUC0-t, AUC from time zero to the last sampling time; AUC0-∞, AUC from time zero to inﬁnite; AUCextrap, extrapolated AUC from
the last sampling time to inﬁnite; Cmax, peak concentration; kel, apparent terminal rate constant; MRT, mean residence time; ND, not determined; t1/2el, apparent terminal
elimination half-life; tmax, time to reach Cmax. an ¼ 1; bn ¼ 4; cn ¼ 3; dn ¼ 2; *p < 0.05, signiﬁcantly different from the verapamil group. Comparisons between the verapamil
(positive control group) vs experimental groups were performed by one-way ANOVA with the post hoc Dunnett's test, the exception was the tmax parameter in which the
nonparametric Kruskal-Wallis with the post hoc Dunn's test was applied.
A. Ferreira et al. / Food and Chemical Toxicology 106 (2017) 446e454 4513.3. Effects of silymarin and EPG combinations on the OXC and LIC
plasma-to-brain biodistribution
As the brain is the target organ (biophase) for the therapeutic
activity of OXC and LIC, an additional study was designed to assess
and compare the impact of the pre-treatment of the three ﬂavonoid
ﬁxed-ratio combinations (silymarin/EPG 1:1, silymarin/EPG 1:3,
silymarin/EPG 3:1) on the OXC and LIC plasma-to-brain bio-
distribution, also using verapamil (a classic P-gp inhibitor) as pos-
itive control. In this case, the animals were sacriﬁced at 1.5 h after
dosing with OXC and the mean concentration levels of OXC and LICFig. 3. Mean plasma and brain tissue concentrations of oxcarbazepine and its active
metabolite licarbazepine obtained at 1.5 h post-dose of oxcarbazepine (50 mg/kg, i.p.)
in rats pre-treated intraperitoneally with silymarin/EPG 1:1 (12.5/12.5 mg/kg; ﬁxed-
ratio combination of 1:1), silymarin/EPG 1:3 (6.25/18.75 mg/kg; ﬁxed-ratio combina-
tion of 1:3), silymarin/EPG 3:1 (18.75/6.25 mg/kg; ﬁxed-ratio combination of 3:1), or
verapamil (25 mg/kg). Data are expressed as the mean values ± standard error of the
mean (SEM) of three determinations (n ¼ 3). Comparisons between the verapamil
(positive control group) vs experimental groups were performed using one-way
ANOVA with the post hoc Dunnett's test.determined in plasma samples and brain tissues are shown in Fig. 3.
Analysing and comparing the obtained results, it is evident that no
statistically signiﬁcant differences were found in the plasma and
brain concentrations of OXC and LIC between the group of rats pre-
treated with verapamil and the groups that received ﬂavonoid
combinations. These ﬁndings support the similar efﬁcacy between
the dual ﬂavonoid combinations tested and verapamil in the
increasing the brain exposure to OXC and LIC, reﬂecting the absence
of differences in the systemic drug exposure observed at the time of
the Cmax (1.500e1.750 h post OXC dose; Table 1).4. Discussion
The disappointment of the standard P-gp inhibitors in over-
coming the drug efﬂux driven by P-gp led to an incessant search for
new therapeutic options. Actually, whereas the clinical use of the
ﬁrst generation P-gp inhibitors (e.g., verapamil or cyclosporine)
was limited due to unacceptable toxicity, the second-generation P-
gp inhibitors (e.g., dexverapamil or valspodar) are involved in un-
predictable pharmacokinetic reactions with other membrane
transporter proteins (Bansal et al., 2009; Ferreira et al., 2015;
Palmeira et al., 2012). In turn, third-generation agents like bir-
icodar, elacridar, laniquidar, tariquidar or zosuquidar have shown to
be promising in clinical trials, but they ended up demonstrating
undesirable side effects in non-target organs (Abraham et al., 2009;
Callies et al., 2003; Stewart et al., 2000). The poor safety proﬁles
exhibited by the early generations of P-gp inhibitors highly
demanded the discovery of compounds that canmodulate the P-gp,
without unacceptable toxicity.
The classiﬁcation of AEDs, as well as their metabolites, as sub-
strates of the P-gp has been a subject of controversy, but some
previous studies give support in this direction. For example, Rizzi
et al. (2002) have shown that the overexpression of P-gp in the
hippocampus of a kainate model of epilepsy was associated with a
reduction in the brain concentrations of phenytoin. Additionally,
several reports evocated the efﬁcacy of the P-gp inhibitors tar-
iquidar, nimodipine and verapamil in overcoming the AEDs phar-
macoresistance in animal models of epilepsy, improving their
anticonvulsant activity (Brandt et al., 2006; H€ocht et al., 2007; van
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studies which support this hypothesis, demonstrating that the
seizure control was improved in two patients with intractable ep-
ilepsy when verapamil was added (Iannetti et al., 2005; Summers
et al., 2004). Indeed, verapamil is reported as the most exten-
sively characterized P-gp inhibitor and multidrug resistance
reversal agent that has entered clinical trials (Iannetti et al., 2005;
Perez-Tomas, 2006; Summers et al., 2004), enhancing the plasma
levels of several AEDs in rats and patients (Al-Humayyd, 1996;
Alvariza et al., 2013; Bahls et al., 1991; Beattie et al., 1988; Neerati
et al., 2011). However, these works also emphasise the toxicity
frequently reported for the ﬁrst generation P-gp inhibitors. The
existing studies involving OXC, in particular, are few but they evi-
dence that OXC and its active metabolite LIC as well, are P-gp
substrates either in in vitro assays (Fortuna et al., 2012; Zhang et al.,
2011) or in humans (Antunes et al., 2016; Zadrozniak et al., 2009).
One of the approaches that has been explored is the combined
use of traditional P-gp inhibitors. In this context, the combination of
verapamil and quinine was tested, and it increased the anthracy-
cline accumulation and retention in multidrug resistant cells to a
greater extent than did either drug individually (Lehnert et al.,
1991). Taking this into consideration, the investigation of the po-
tential of ﬂavonoid combinations as P-gp inhibitors for reversing
the resistance to the treatment with OXC emerged as a pertinent
topic of research. The interest of ﬂavonoids as P-gp inhibitors has
been increasingly evoked, with some of them producing effects
comparable to those of the classic P-gp inhibitors, like verapamil or
cyclosporine A (Bansal et al., 2009; Brandt et al., 2006; Ferreira
et al., 2015; Mohana et al., 2016; Schinkel and Jonker, 2012). The
combined use of ﬂavonoid compounds for therapeutic approaches
is not a new idea. Actually, the synergistic effects of ﬂavonoid
combinations were previously demonstrated for several other ac-
tivities. For instance, the combination of baicalein and daidzein
demonstrated to exert synergistic effects in estrogenic and neuro-
protective activities (Choi et al., 2013); the combination of quer-
cetin and kaempferol enhanced the in vitro cytotoxicity on human
colon cancer (HCT-116) cells (Jaramillo-Carmona et al., 2014);
chrysin, kaempferol, morin, and silybin combinations produced a
synergistic inhibition of proinﬂammatory mediator secretion from
lipopolysaccharide-induced RAW 264.7 cells (Harasstani et al.,
2010); whereas the combination of the formononetin, ononin,
calycosin and calycosin-7-O-b-D-glucosidemay have a strong effect
in activating the regulatory element of erythropoietin at very low
dosage (Yu et al., 2013).
Regarding this therapeutic approach, the current study was
planned to evaluate the potential of the combined use of the ﬂa-
vonoids silymarin and EPG, recognised as P-gp inhibitors, in
improving the pharmacokinetics of OXC, and of its pharmacologi-
cally active metabolite LIC, when comparing to the standard P-gp
inhibitor verapamil. The ability of silymarin and EPG in inhibiting
the P-gp in vitro has been previously demonstrated (Chung et al.,
2005; Jodoin et al., 2002; Kitagawa et al., 2004; Zhang and
Morris, 2003b). To the best of our knowledge, only silymarin has
been investigated in vivo for this purpose and it has shown to
signiﬁcantly enhance the bioavailability of the P-gp substrate
paclitaxel in Sprague-Dawley rats (Park et al., 2012). Epi-
gallocatechin (not gallate) also demonstrated to signiﬁcantly in-
crease the bioavailability of the P-gp substrate diltiazem in
Sprague-Dawley rats (Li and Choi, 2008).
The results of the present work, support that silymarin and EPG
combinations have a higher impact than their individual use in
improving the magnitude of systemic exposure to OXC (as assessed
by Cmax). Nevertheless, such effects were not observed in the extent
of systemic drug exposure (AUC0-t) when comparing with the
group pre-treated with verapamil. Thus, these results suggest thatthe pharmacological activity induced silymarin/EPG combinations
is similar to that of verapamil in terms of potency, but the effect of
verapamil appears to be more prolonged in time. This difference
may be related with the different drug-like properties of verapamil
and silymarin/EPG, as they were all administered at a ﬁxed dose of
25 mg/kg. Therefore, these ﬁndings suggest the need of further
studies using higher doses of ﬂavonoid combinations, until
acceptable levels in terms of safety concerns, or even chemically
modify some of the functional groups of these ﬂavonoid-type
compounds to improve their druggability. Other options that
deserve to be explored in the future to extend the duration of action
of ﬂavonoid compounds will be the use of new delivery strategies
and improved formulations in order to achieve greater advantages
of the ﬂavonoids pharmacological potential, including as P-gp in-
hibitors. In addition, it can be highlighted that for LIC no statistically
signiﬁcant differences were observed between all the ﬂavonoids
experimental groups and the positive control group (verapamil) for
the pharmacokinetic parameters tmax and Cmax. Moreover, as ex-
pected, the close similarity observed in the systemic effects induced
by dual ﬂavonoid combinations and verapamil at the time the
maximum plasma concentrations were reached for OXC and LIC
was also found in brain (biophase). Indeed, no statistically signiﬁ-
cant differences were found in the brain exposure to OXC and LIC
after the pre-treatment of the rats with the ﬂavonoid combinations
or verapamil. This potential exhibited by the ﬂavonoids silymarin
and EPG, when compared to the standard P-gp inhibitor verapamil,
is of great signiﬁcance mainly taking into account the toxicity
proﬁle reported for the latter.
Although the exact mechanisms underlying ﬂavonoid-P-gp in-
teractions are not clear, several hypotheses have been proposed.
Nevertheless, the combined use of ﬂavonoids could beneﬁt from
the existence of multiple binding sites for substrates and inhibitors
on the P-gp (Yang and Liu, 2004). Particularly, silymarin and EPG
are known to inhibit P-gp functions acting as substrate, and they
may interact with P-gp directly either by competitive binding to the
substrate-binding site or by binding to other drug-binding sites and
changing the P-gp conformation (Jodoin et al., 2002; Kwon et al.,
2006; Zhang and Morris, 2003b). Considering that dual combina-
tions of silymarin and EPG improved the pharmacokinetics of OXC
and LIC (P-gp substrates), when comparing to their individual ef-
fects, we could hypothesise that these two ﬂavonoids have different
and complementary molecular mechanisms underlying ﬂa-
vonoideP-gp in vivo interactions. Actually, this hypothesis is sup-
ported by the observation of opposite and complementary effects
on P-gp ATPase activity for different ﬂavonoids (Zhang and Morris,
2003a).
The combined used of silymarin and EPG could be relevant in
overpassing the P-gp-mediated pharmacoresistance in epilepsy,
but it should also be highlighted other neuropharmacological
properties ascribed to ﬂavonoids with therapeutic interest in this
scope, particularly as antiepileptic/anticonvulsant drugs (Abbasi
et al., 2012; Hu et al., 2011; Nassiri-Asl et al., 2014, 2013; Romano
et al., 2013; Yoon et al., 2011). Speciﬁcally, the Silybum marianum
seeds extract, in which silymarin is the bioactive constituent, and
EPG demonstrated to have anticonvulsant effects on
pentylenetetrazol-kindled seizure in mice and rats, respectively
(Waqar et al., 2016; Xie et al., 2012). Hence, these ﬂavonoid-type
compounds emerge as natural compounds of interest not only as
an add-on therapy to optimize the AED treatment in drug-resistant
epilepsy, but also to directly potentiate their anticonvulsant
activity.
5. Conclusions
The disappointment brought by the classical P-gp inhibitors
A. Ferreira et al. / Food and Chemical Toxicology 106 (2017) 446e454 453agents in overcoming the P-gp-mediated drug efﬂux has led to an
incessant search for new non-cytotoxic inhibitors and novel ap-
proaches for their use as well. To the best of our knowledge, this is
the ﬁrst work evidencing the synergistic effects of dual ﬂavonoid
combinations of silymarin and EPG in enhancing the magnitude of
systemic exposure to OXC and LIC in rats in a similar potency to that
exhibited by verapamil (a reference P-gp inhibitor). Hence, our
ﬁndings support that the strategy of combining ﬂavonoid-type P-
gp inhibitors should continue to be exploited for the management
of the pharmacoresistant epilepsy.
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